Efrén Ocampo, CEO of the Mexican pharmaceutical group Neolpharma, details the strategic thinking that has fostered the emergence of one of the most prominent healthcare groups in Mexico and the challenges and opportunities that lie ahead in Mexico and abroad.
Neolpharma Group encompasses five manufacturing companies and 14 other service providing companies. Could you explain the strategic thinking that has led the current structure of the group?
The significance of our overall portfolio puts us in a privileged position to service rural, urban and semi-urban areas of Mexico, which all display different epidemiological profiles that need to be distinctively approached.
